Mechanism of anti-cancer effect of β-glucan on SH-SY5Y cell line
Keywords:Apoptosis, Cell viability, β-glucan, DNA damage, ELISA, SH-SY5Y cell, XTT assay
Anti-cancer property of fungi derived β-glucan (Lentinula edodes) on several cancer cell lines have been reported. In this work, the SH-SY5Y cell lines were treated with various concentrations of β-glucan (62.5, 125, 250 and 500 μg/mL) and the viability of the cells was tested using the XTT assay after 24 hours. Cleaved PARP, BCL-2, 8-hydroxy-desoxyguanosine (8-oxo-dG), cleaved caspase 3, Bax, total oxidant, and total antioxidant levels in the cells were measured by commercial kits. β-Glucan significantly decreased the cell viability in SH-SY5Y cells. ELISA tests demonstrated that β-glucan therapy dramatically increased 8-oxo-dG, cleaved caspase 3, Bax, cleaved PARP, total oxidant. However, β-glucan treatment did not change the BCL-2 protein level. Altogether, β-glucan caused significant cytotoxicity in SH-SY5Y cells by inducing oxidative stress, increasing DNA damage, and ultimately increasing apoptosis.
Atiq A, Parhar I. Anti-neoplastic Potential of Flavonoids and Polysaccharide Phytochemicals in Glioblastoma. Molecules 2020; 25: 4895.
Baig S, Seevasant I, Mohamad J, Mukheem A, Huri HZ, Kamarul T. Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand? Cell Death Dis. 2016; 7: e2058.
Chen J. Recent advance in the studies of β-glucans for cancer therapy. Anticancer Agents Med Chem. 2013; 13: 679-80.
Chen J, Huang XF. The effects of diets enriched in beta-glucans on blood lipoprotein concentrations. J Clin Lipidol. 2009; 3: 154-58.
Chen Z, Zhang B, Gao F, Shi R. Modulation of G2/M cell cycle arrest and apoptosis by luteolin in human colon cancer cells and xenografts. Oncol Lett. 2018; 15: 1559-65.
Cheung NK, Modak S. Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res. 2002; 8: 1217-23.
Choromanska A, Kulbacka J, Harasym J, Oledzki R, Szewczyk A, Saczko J. High- and low-molecular weight oat beta-glucan reveals antitumor activity in human epithelial lung cancer. Pathol Oncol Res. 2018; 24: 583-92.
Choromanska A, Kulbacka J, Rembialkowska N, Pilat J, Oledzki R, Harasym J, Saczko J. Anticancer properties of low molecular weight oat beta-glucan: An in vitro study. Int J Biol Macromol. 2015; 80: 23-28.
Di Luzio NR, Williams DL, McNamee RB, Edwards BF, Kitahama A. Comparative tumor-inhibitory and antibacte-rial activity of soluble and particulate glucan. Int J Cancer. 1979; 24: 773-79.
Elmore S. Apoptosis: A review of programmed cell death. Toxicol Pathol. 2007; 35: 495-516.
Ergul M, Bakar-Ates F. A specific inhibitor of polo-like kinase 1, GSK461364A, suppresses proliferation of Raji Burkitt's lymphoma cells through mediating cell cycle arrest, DNA damage, and apoptosis. Chem Biol Interact. 2020; 332: 109288.
Ergul M, Bakar-Ates F. Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells. Toxicol In Vitro. 2021; 73: 105138.
Guo C, Li X, Wang R, Yu J, Ye M, Mao L, Zhang S, Zheng S. Association between oxidative DNA damage and risk of colorectal cancer: Sensitive determination of urinary 8-hydroxy-2'-deoxyguanosine by UPLC-MS/MS analysis. Sci Rep. 2016; 6: 32581.
Inoue K, Takano H, Oda T, Yanagisawa R, Tamura H, Adachi Y, Ishibashi K, Ohno N. Soluble cell wall beta-glucan of Candida induces/enhances apoptosis and oxidative stress in murine lung. Immunopharmacol Immunotoxicol. 2009; 31: 140-45.
Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther. 2005; 4: 139-63.
Kim MJ, Hong SY, Kim SK, Cheong C, Park HJ, Chun HK, Jang KH, Yoon BD, Kim CH, Kang SA. beta-Glucan enhanced apoptosis in human colon cancer cells SNU-C4. Nutr Res Pract. 2009; 3: 180-84.
Kushner BH, Cheung IY, Modak S, Kramer K, Ragupathi G, Cheung NK. Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission. Clin Cancer Res. 2014; 20: 1375-82.
Ladenstein R, Pötschger U, Hartman O, Pearson AD, Klingebiel T, Castel V, Yaniv I, Demirer T, Dini G, EBMT Paediatric Working Party. 28 Years of high-dose therapy and SCT for neuroblastoma in Europe: Lessons from more than 4000 procedures. Bone Marrow Transplant. 2008; 41: S118-27.
Laverdière C, Cheung NK, Kushner BH, Kramer K, Modak S, LaQuaglia MP, Wolden S, Ness KK, Gurney JG, Sklar CA. Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer. 2005; 45: 324-32.
Lee SI, Jeong YJ, Yu AR, Kwak HJ, Cha JY, Kang I, Yeo EJ. Carfilzomib enhances cisplatin-induced apoptosis in SK-N-BE(2)-M17 human neuroblastoma cells. Sci Rep. 2019; 9: 5039.
Mantovani MS, Bellini MF, Angeli JP, Oliveira RJ, Silva AF, Ribeiro LR. beta-Glucans in promoting health: Prevention against mutation and cancer. Mutat Res. 2008; 658: 154-61.
Matos CP, Adiguzel Z, Yildizhan Y, Cevatemre B, Onder TB, Cevik O, Nunes P, Ferreira LP, Carvalho MD, Campos DL, Pavan FR, Pessoa JC, Garcia MH, Tomaz AI, Correia I, Acilan C. May iron (III) complexes containing phenan-throline derivatives as ligands be prospective anticancer agents? Eur J Med Chem. 2019; 176: 492-512.
Moreno L, Caron H, Geoerger B, Eggert A, Schleiermacher G, Brock P, Valteau-Couanet D, Chesler L, Schulte JH, De Preter K, Molenaar J, Schramm A, Eilers M, Van Maerken T, Johnsen JI, Garrett M, George SL, Tweddle DA, Kogner P, Berthold F, Koster J, Barone G, Tucker ER, Marshall L, Herold R, Sterba J, Norga K, Vassal G, Pearson AD. Accelerating drug development for neuroblastoma - New drug development strategy: An innovative therapies for children with cancer, European network for cancer research in children and adolescents and International Society of Paediatric Oncology Europe neuroblastoma project. Expert Opin Drug Discov. 2017; 12: 801-11.
Nolan JC, Frawley T, Tighe J, Soh H, Curtin C, Piskareva O. Preclinical models for neuroblastoma: Advances and challenges. Cancer Lett. 2020; 474: 53-62.
Quinn PJ. Mechanisms of action of some immunomodulators used in veterinary medicine. Adv Vet Sci Comp Med. 1990; 35: 43-99.
Sachdev E, Tabatabai R, Roy V, Rimel BJ, Mita MM. PARP Inhibition in cancer: An update on clinical development. Target Oncol. 2019; 14: 657-79.
Sima P, Richter J, Vetvicka V. Glucans as new anticancer agents. Anticancer Res. 2019; 39: 3373-78.
Suebsoonthron J, Jaroonwitchawan T, Yamabhai M, Noisa P. Inhibition of WNT signaling reduces differentiation and induces sensitivity to doxorubicin in human malignant neuroblastoma SH-SY5Y cells. Anticancer Drugs. 2017; 28: 469-79.
Tang H, Zhang Y, Li D, Fu S, Tang M, Wan L, Chen K, Liu Z, Xue L, Peng A, Ye H, Chen L. Discovery and synthesis of novel magnolol derivatives with potent anticancer activity in non-small cell lung cancer. Eur J Med Chem. 2018; 156: 190-205.
Taskiran A S, Ergul M. Oxytocin promotes C6 glial cell death and aggravates hydrogen peroxide-induced oxidative stress. INNOSC Theranostics Pharmacol Sci. 2020 ; 3: 27-33.
Taskiran AS, Ergul M. The modulator action of thiamine against pentylenetetrazole-induced seizures, apoptosis, nitric oxide, and oxidative stress in rats and SH-SY5Y neuronal cell line. Chem Biol Interact. 2021; 340: 109447.
Vannucci L, Krizan J, Sima P, Stakheev D, Caja F, Rajsiglova L, Horak V, Saieh M. Immunostimulatory properties and anti-tumor activities of glucans (review). Int J Oncol. 2013; 43: 357-64.
Xu HL, Dai JH, Hu T, Liao YF. Lentinan up-regulates micro-RNA-340 to promote apoptosis and autophagy of human osteosarcoma cells. Int J Clin Exp Pathol. 2018; 11: 3876-83.
Xu H, Zou S, Xu X, Zhang L. Anti-tumor effect of β-glucan from Lentinus edodes and the underlying mechanism. Sci Rep. 2016; 6: 28802.
Zhang L, Li X, Xu X, Zeng F. Correlation between antitumor activity, molecular weight, and conformation of lentinan. Carbohydr Res. 2005; 340: 1515-21.
Zhang M, Chiu LC, Cheung PC, Ooi VE. Growth-inhibitory effects of a beta-glucan from the mycelium of Poria cocos on human breast carcinoma MCF-7 cells: Cell-cycle arrest and apoptosis induction. Oncol Rep. 2006; 15: 637-43.
Zhang X, Li T, Liu S, Xu Y, Meng M, Li X, Lin Z, Wu Q, Xue Y, Pan Y, Alitongbieke G. β-glucan from Lentinus edodes inhibits breast cancer progression via the Nur77/HIF-1α axis. Biosci Rep. 2020; 40: BSR20201006.
Zhang Y, Li Q, Wang J, Cheng F, Huang X, Cheng Y, Wang K. Polysaccharide from Lentinus edodes combined with oxaliplatin possesses the synergy and attenuation effect in hepatocellular carcinoma. Cancer Lett. 2016; 377: 117-25.
How to Cite
Copyright (c) 2021 Ahmet Kemal Filiz, Ziad Joha, Fatih Yulak
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).